#United States #Chicago #DELFI Diagnostics #cancer detection #fragmentomics

DELFI Diagnostics to Present at AACR Annual Meeting

DELFI Diagnostics, a pioneer in blood-based tests utilizing cell-free DNA (cfDNA) fragmentomics, has announced its participation in the 2025 American Association for Cancer Research (AACR) Annual Meeting. This prestigious event, taking place in Chicago, IL, will feature notable presentations from DELFI regarding its innovative DELFI-TF technology designed for advanced cancer monitoring and early detection capabilities.

Victor E. Velculescu, the founder and board director of DELFI Diagnostics, expressed enthusiasm about the forthcoming presentations. He stated that the company’s fragmentomics platform is revolutionizing how cancer is detected and monitored. By integrating genome-wide fragmentomics with artificial intelligence, DELFI aims to achieve high sensitivity for early cancer detection and effectively assess treatment responses in advanced cancer patients.

The presentations scheduled at AACR include:

• - Genomic and Fragmentomic Landscapes of Cell-Free DNA for Early Detection

Presented by: Victor E. Velculescu, MD, PhD
Date and Time: April 29, 11:06 AM - 11:26 AM CT
Location: Room S100 BC, McCormick Place South

• - Leveraging the cfDNA Fragmentome to Predict Immunotherapy Response

Presented by: Valsamo Anagnostou, MD, PhD
Date and Time: April 28, 3:05 PM - 3:20 PM CT
Location: Room S105, McCormick Place South

• - Analysis of Lung Cancer Clinical Characteristics Using cfDNA Fragmentomes

Presented by: Lorenzo Rinaldi, PhD
Date and Time: April 28, 9:00 AM - 12:00 PM CT
Location: Section 28, Poster 29

• - Cell-Free DNA Fragmentomes for Treatment Response Monitoring in Patients with Metastatic Colorectal Cancer: The DOLPHIN Study

Presented by: Denise E. Van Steijn
Date and Time: April 28, 2:00 PM - 5:00 PM CT
Location: Section 29, Poster 6

DELFI Diagnostics has previously validated its FirstLook Lung test, which focuses on enhancing early detection of lung cancer — a leading cause of cancer-related deaths in the United States. This meeting will also feature additional research on early detection in various cancers, including liver and ovarian cancers.

In an exciting development, DELFI Diagnostics launched its DELFI-TF research service in February 2024. This service has proven instrumental in aiding major pharmaceutical companies in making critical decisions throughout oncology drug development. The DELFI-TF technology offers a comprehensive monitoring process throughout the metastatic cancer journey, requiring only 800µl of plasma, achieving a remarkable success rate of 99% with results typically delivered within 10 to 14 business days.

Moreover, DELFI-TF has established its capability to accurately monitor tumor burden independent of mutation profiling, aligning strongly with measurements of the Mutant Allele Frequency (MAF) even when specific mutations are absent.

Nicholas C. Dracopoli, Chief Scientific Officer and Co-Founder, emphasized the importance of DELFI-TF in the oncology landscape. He noted that the lack of efficacy remains a primary reason for Phase II clinical trial failures, underscoring the need for improved efficacy detection methods in early clinical trials. DELFI-TF's design allows pharmaceutical developers to efficiently monitor treatment responses earlier than traditional approaches.

For individuals interested in learning more about DELFI Diagnostics and its pioneering fragmentomics technology, the company invites attendees to visit them at Booth #2060 during the AACR Annual Meeting or explore their offerings at www.delfidiagnostics.com.

Note: The DELFI-TF Assay and related services are intended solely for research purposes and not for diagnostic applications.

About DELFI Diagnostics

DELFI Diagnostics is on a mission to develop advanced, blood-based tests that provide accurate, accessible cancer detection solutions. These innovative tests are particularly focused on improving health outcomes in populations with the highest burdens, particularly underserved demographics, potentially saving lives worldwide. The FirstLook Lung assay represents their commitment to providing simple, effective cancer screening solutions, harnessed through cutting-edge technologies that analyze cfDNA patterns in the blood. Such advancements position DELFI at the forefront of a paradigm shift in cancer detection.